123 related articles for article (PubMed ID: 13299814)
1. [Nerves of human breast benign and malignant tumors].
POL'KINA RI
Vopr Onkol; 1955; 1(4):22-9. PubMed ID: 13299814
[No Abstract] [Full Text] [Related]
2. Ultrasonic Nakagami imaging: a strategy to visualize the scatterer properties of benign and malignant breast tumors.
Tsui PH; Yeh CK; Liao YY; Chang CC; Kuo WH; Chang KJ; Chen CN
Ultrasound Med Biol; 2010 Feb; 36(2):209-17. PubMed ID: 20018436
[TBL] [Abstract][Full Text] [Related]
3. Phytosterols and cholesterol in malignant and benign breast tumors.
Mellies MJ; Ishikawa TT; Glueck CJ; Crissman JD
Cancer Res; 1977 Sep; 37(9):3034-6. PubMed ID: 884660
[TBL] [Abstract][Full Text] [Related]
4. Intravoxel incoherent motion (IVIM) in evaluation of breast lesions: comparison with conventional DWI.
Liu C; Liang C; Liu Z; Zhang S; Huang B
Eur J Radiol; 2013 Dec; 82(12):e782-9. PubMed ID: 24034833
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of miR-9 in benign and malignant breast tumors.
Hasanzadeh A; Mesrian Tanha H; Ghaedi K; Madani M
Mol Cell Probes; 2016 Oct; 30(5):279-284. PubMed ID: 27725294
[TBL] [Abstract][Full Text] [Related]
6. Diffusion weighted imaging for the differentiation of breast tumors: From apparent diffusion coefficient to high order diffusion tensor imaging.
Teruel JR; Goa PE; Sjøbakk TE; Østlie A; Fjøsne HE; Bathen TF
J Magn Reson Imaging; 2016 May; 43(5):1111-21. PubMed ID: 26494124
[TBL] [Abstract][Full Text] [Related]
7. Differential Diagnosis of Benign and Malignant Breast Tumors Using Apparent Diffusion Coefficient Value Measured Through Diffusion-Weighted Magnetic Resonance Imaging.
Qu RF; Guo DR; Chang ZX; Meng J; Sun Y; Hao SH; Shi G; Sun J
J Comput Assist Tomogr; 2015; 39(4):513-22. PubMed ID: 25783797
[TBL] [Abstract][Full Text] [Related]
8. [Distinguishing benign and malignant lesions with time-signal intensity curve of dynamic contrast-enhanced breast MRI scanning].
Yuan HM; Yu JQ; Chu ZG; Peng LQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 42(4):556-9. PubMed ID: 21866648
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of benign and malignant breast tumors using Doppler spectral parameters including acceleration time index.
Mesaki K; Hisa N; Kubota K; Hisa N; Ogawa Y; Yoshida S
Oncol Rep; 2003; 10(4):945-50. PubMed ID: 12792750
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.
Tahiri A; Leivonen SK; Lüders T; Steinfeld I; Ragle Aure M; Geisler J; Mäkelä R; Nord S; Riis ML; Yakhini Z; Kleivi Sahlberg K; Børresen-Dale AL; Perälä M; Bukholm IR; Kristensen VN
Carcinogenesis; 2014 Jan; 35(1):76-85. PubMed ID: 24104550
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.
Karami-Tehrani F; Moeinifard M; Aghaei M; Atri M
Arch Med Res; 2012 Aug; 43(6):470-5. PubMed ID: 22960860
[TBL] [Abstract][Full Text] [Related]
12. Improving suspicious breast lesion characterization using semi-automatic lesion fractional volume washout kinetic analysis.
Huang J; Hahn T; Hoisington L; Schafer S; Zong X; Berger K
Med Phys; 2011 Nov; 38(11):5998-6009. PubMed ID: 22047364
[TBL] [Abstract][Full Text] [Related]
13. [Malignant degeneration of benign tumors of the breast].
VOGEL G
Strahlentherapie; 1952; 87(1):150-1. PubMed ID: 14931128
[No Abstract] [Full Text] [Related]
14. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions.
Zhao H; Xu R; Ouyang Q; Chen L; Dong B; Huihua Y
Eur J Radiol; 2010 Feb; 73(2):288-93. PubMed ID: 19559551
[TBL] [Abstract][Full Text] [Related]
15. [Histological and endocrinological relationship between malignant and benign tumors of the breast].
TOKUYAMA H; SAWADA A; MIZOTA S; TUKADA K
Gan; 1955 Sep; 46(2-3):311-3. PubMed ID: 13262381
[No Abstract] [Full Text] [Related]
16. Strain-compounding technique with ultrasound Nakagami imaging for distinguishing between benign and malignant breast tumors.
Liao YY; Li CH; Tsui PH; Chang CC; Kuo WH; Chang KJ; Yeh CK
Med Phys; 2012 May; 39(5):2325-33. PubMed ID: 22559602
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors.
Karami-Tehrani F; Malek AR; Shahsavari Z; Atri M
Tumour Biol; 2016 Jul; 37(7):8849-56. PubMed ID: 26749282
[TBL] [Abstract][Full Text] [Related]
18. Perfusion heterogeneity in breast tumors for assessment of angiogenesis.
Li YJ; Wen G; Wang Y; Wang DX; Yang L; Deng YJ; Wei HQ; He J; Zhang X; Gu YS
J Ultrasound Med; 2013 Jul; 32(7):1145-55. PubMed ID: 23804337
[TBL] [Abstract][Full Text] [Related]
19. [Hemodynamic changes in benign and malignant breast tumors and the mechanism].
Li YJ; Yang L; Xia Q; Wen G
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug; 29(8):1557-60. PubMed ID: 19726291
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
